The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Open accessAbstract
Two general approaches to the treatment of type 2 diabetes mellitus (T2DM) have been advocated. 1 ) A “guideline” approach that advocates sequential addition of antidiabetes agents with “more established use” (1); this approach more appropriately should be called the “treat to failure” approach, and deficiencies with this approach have been discussed (2). And 2 ) a “pathophysiologic” approach using initial combination therapy with agents known to correct established pathophysiologic defects in T2DM (3). Within the pathophysiologic approach, choice of antidiabetes agents should take into account the patient’s general health status and associated medical disorders. This individualized approach, which we refer to as the ABCD(E) of diabetes treatment (4), has been incorporated into the updated American Diabetes Association (ADA) guidelines (5). Even though physicians must be cognizant of these associated conditions (ABCDE) when initiating therapy in newly diagnosed T2DM patients, we believe that the most important consideration is to select antidiabetes agents that correct specific pathophysiologic disturbances present in T2DM and that have complementary mechanisms of action. Although it has been argued that the pathogenesis of T2DM differs in different ethnic groups (6), evidence to support this is weak. Although the relative contributions of β-cell failure and insulin resistance to development of glucose intolerance may differ in different ethnic groups (6), the core defects of insulin resistance in muscle/liver/adipocytes and progressive β-cell failure (3) are present in virtually all T2DM patients and must be treated aggressively to prevent the relentless rise in HbA1c that is characteristic of T2DM. In subsequent sections, we provide a review of the natural history of T2DM, specific pathophysiologic abnormalities responsible for T2DM, currently …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Insulin Binding to Monocytes and Insulin Action in Human Obesity, Starvation, and Refeeding
Defronzo, R. A., Soman, V., Sherwin, R. S., Hendler, R., & Felig, P. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109108 · Cited by 252
Self-citationRetractedTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Self-citationU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationLillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Self-citationLong-term weight-loss maintenance: a meta-analysis of US studies
Anderson, J. W., Konz, E. C., Frederich, R. C., & Wood, C. L. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.5.579 · Cited by 1,351
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Self-citationDeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167
Self-citationLim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., & Mandarino, L. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7535 · Cited by 1,139
Self-citationToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citationNissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 5×
“in 2,3,8,40), including impaired glucose transport/phosphorylation (17), reduced glycogen synthesis (39), and decreased glucose oxidation (17).”
BackgroundMethodInfluentialSelf-citationEarly Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 1×
“phase 3 trials (162,163), pioglitazone slows progression of carotid intimalmedia thickness (87,152) and reduces coronary atheroma volume (88).”
BackgroundSelf-citationon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
International Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats
Obici, S., Feng, Z., Karkanias, G., Baskin, D. G., & Rossetti, L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-861 · Cited by 719
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
(1997) · Diabetes reviews · Cited by 671
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationAronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Impaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
Wright, A., Burden, A. C. F., Paisey, R. B., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.2.330 · Cited by 556
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 5×
“Lower panel: Mean plasma glucose concentration during OGTT.”
BackgroundInfluentialSelf-citationFonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 2×
“In liver, insulin resistance is manifested by glucose overproduction during the basal state despite fasting hyperinsulinemia (16) and impaired suppression of hepatic glucose production (HGP) by insulin (17), as occurs following a meal (18).”
BackgroundSelf-citationGoldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationHerman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
Self-citationEffect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474
Meta-analysis: The Effect of Dietary Counseling for Weight Loss
Dansinger, M. L., Tatsioni, A., Wong, J. B., Chung, M., & Balk, E. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00007 · Cited by 467
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Cusi, K. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4059 · Cited by 455
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Self-citationGlucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Zinman, B., Hoogwerf, B. J., Durán García, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 427
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418
The natural history of impaired glucose tolerance in the Pima Indians
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., Mott, D. M., & Bennett, P. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812083192302 · Cited by 413 · cited 1×
“Similar conclusions are evident from other publications (24,27,34,35).”
ResultPatrono, C. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.10.013 · Cited by 408
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · cited 2×
“This protective effect has its onset within 24 h (86) and persists as long as GLP-1 therapy is continued (84,85,93).”
BackgroundNatali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Self-citationCentral melanocortin receptors regulate insulin action
Obici, S., Feng, Z., Tan, J., Liu, L., Karkanias, G., & Rossetti, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12954 · Cited by 371
Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 368
Weyer, C., Tataranni, P. A., Bogardus, C., & Pratley, R. E. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.89 · Cited by 357
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60691-6 · Cited by 343
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Self-citationSulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets
Maedler, K., Carr, R. D., Bosco, D., Zuellig, R. A., Berney, T., & Donath, M. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0699 · Cited by 333
Garratt, K. N., Brady, P. A., Hassinger, N. L., Grill, D. E., Terzic, A., & Holmes, D. R. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00557-9 · Cited by 332
Metformin: A review of its metabolic effects
Cusi, K. J., & DeFronzo, R. A. (1998) · Diabetes reviews · Cited by 310
Self-citationBaron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
The disposal of an oral glucose load in patients with non-insulin-dependent diabetes
Ferrannini, E., Simonson, D. C., Katz, L. D., Reichard, G., Bevilacqua, S., Barrett, E. J., Olsson, M., & DeFronzo, R. A. (1988) · Metabolism · doi:10.1016/0026-0495(88)90033-9 · Cited by 305
Self-citationThe evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes
Bergman, R. N., Finegood, D. T., & Kahn, S. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.5.x · Cited by 301
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Roumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
Self-citationMiyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274
Self-citationAltered hypothalamic function in response to glucose ingestion in obese humans.
Matsuda, M., Liu, Y., Mahankali, S., Pu, Y., Mahankali, A., Wang, J., DeFronzo, R. A., Fox, P. T., & Gao, J. H. (1999) · Diabetes · doi:10.2337/diabetes.48.9.1801 · Cited by 274
Self-citationQuantitation of Endocrine Cell Content in the Pancreas of Nondiabetic and Diabetic Humans
Stefan, Y., Orci, L., Malaisse-Lagae, F., Perrelet, A., Patel, Y., & Unger, R. H. (1982) · Diabetes · doi:10.2337/diab.31.8.694 · Cited by 272
Saad, M., Pettitt, D., Mott, D., Knowler, W., Nelson, R., & Bennett, P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92804-3 · Cited by 265
Thiazolidinediones and Heart Failure
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · Diabetes Care · doi:10.2337/dc07-0141 · Cited by 262
Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes
Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.517 · Cited by 236
Self-citationSimpson, S. H. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050748 · Cited by 235
Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Mogensen, C. E. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109090668 · Cited by 221
Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Chang, A. M., Jakobsen, G., Sturis, J., Smith, M. J., Bloem, C. J., An, B., Galecki, A., & Halter, J. B. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1786 · Cited by 207
U.K. Prospective Diabetes Study Group (1998) · Diabetes Care · doi:10.2337/diacare.21.1.87 · Cited by 202
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationMatthews, D. R., Dejager, S., Ahren, B., Fonseca, V., Ferrannini, E., Couturier, A., Foley, J. E., & Zinman, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01233.x · Cited by 199
Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin
Lupi, R., Del Guerra, S., Fierabracci, V., Marselli, L., Novelli, M., Patanè, G., Boggi, U., Mosca, F., Piro, S., Del Prato, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s134 · Cited by 186
The fundamental drivers of the obesity epidemic
James, W. P. T. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00432.x · Cited by 179 · cited 1×
“epidemic of obesity and physical inactivity (21), which are insulin-resistant states (22) and place stress on pancreatic b-cells to augment insulin secretion to offset insulin resistance (2,3,8).”
BackgroundMigoya, E. M., Bergeron, R., Miller, J. L., Snyder, R. N. K., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 179
Secondary Failure of Metformin Monotherapy in Clinical Practice
Brown, J. B., Conner, C., & Nichols, G. A. (2010) · Diabetes Care · doi:10.2337/dc09-1749 · Cited by 178
Matthews, D. R., Charbonnel, B. H., Hanefeld, M., Brunetti, P., & Schernthaner, G. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.478 · Cited by 175
Dungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173
Charbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1751-1 · Cited by 170
Ahlqvist, E., Ahluwalia, T. S., & Groop, L. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.157016 · Cited by 166
Mulherin, A. J., Oh, A. H., Kim, H., Grieco, A., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 161
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C. L., Musi, N., DeFronzo, R. A., & Cersósimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 159
Self-citationBajaj, M., Suraamornkul, S., Hardies, L. J., Pratipanawatr, T., & DeFronzo, R. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802625 · Cited by 159
Self-citationGallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
Lupi, R., Guerra, S. D., Marselli, L., Bugliani, M., Boggi, U., Mosca, F., Marchetti, P., & Prato, S. D. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00561.2002 · Cited by 151
Bajaj, M., Suraamornkul, S., Hardies, L. J., Glass, L. C., Musi, N., & DeFronzo, R. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0698-9 · Cited by 141
Self-citationEnhanced secretion of glucagon-like peptide 1 by biguanide compounds
Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., & Tanaka, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02565-2 · Cited by 137
Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients
Miyazaki, Y., He, H., Mandarino, L. J., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.8.1943 · Cited by 135
Self-citationMetabolic and molecular basis of insulin resistance
Bajaj, M., & DeFronzo, R. A. (2003) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(03)00520-8 · Cited by 131
Self-citationMechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy.
Shulman, G. I., Rothman, D. L., Smith, D. J. B., Johnson, C. M., Blair, J. B., Shulman, R. G., & DeFronzo, R. A. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112078 · Cited by 128
Self-citationIn Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 128
Self-citationEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Gerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach
Pozzilli, P., Leslie, R. D., Chan, J. C. N., Fronzo, R. D., Monnier, L., Raz, I., & Prato, S. D. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1092 · Cited by 115
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.736 · Cited by 112
Tan, M. H., Baksi, A. J., Krahulec, B., Kubalski, P., Stankiewicz, A., Urquhart, R., Edwards, G., Johns, D., & for the GLAL Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.3.544 · Cited by 111
Marso, S. P., Lindsey, J. B., Stolker, J. M., House, J. A., Ravn, G. M., Kennedy, K. F., Jensen, T. M., & Buse, J. B. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111408937 · Cited by 105
DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104
Self-citationβ-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy
Harrison, L., ADAMS-HUET, B. A., Raskin, P., & Lingvay, I. (2012) · Diabetes Care · doi:10.2337/dc11-2170 · Cited by 101
DeFronzo, R. A., Burant, C., Fleck, P. R., Wilson, C., Mekki, Q. A., & Pratley, R. E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2243 · Cited by 101
Self-citationSchernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B. H., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R. W., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 98
Self-citationEffects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge, D. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00715.x · Cited by 91
Rosenstock, J., Rood, J. A., Cobitz, A. R., Biswas, N., Chou, H. S., & Garber, A. J. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00659.x · Cited by 90
Miyazaki, Y., & DeFronzo, R. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00880.x · Cited by 89
Self-citationEffects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Bajaj, M. S., Baig, R., Suraamornkul, S., Hardies, L. J., Coletta, D. K., Cline, G. W., Monroy, A., Koul, S., Sriwijitkamol, A., Musi, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0911 · Cited by 88
Self-citationPendergrass, M., Bertoldo, A., Bonadonna, R., Nucci, G., Mandarino, L., Cobelli, C., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00617.2005 · Cited by 87
Self-citationPantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2010) · Diabetes Care · doi:10.2337/dc10-0017 · Cited by 87
The Effect of Pioglitazone on the Liver
Gastaldelli, A., Miyazaki, Y., Mahankali, A., Berria, R., Pettiti, M., Buzzigoli, E., Ferrannini, E., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2445 · Cited by 87
Self-citationPeroxisomal Proliferator-Activated Receptor-γ Upregulates Glucokinase Gene Expression in β-Cells
Kim, H.-I., Cha, J.-Y., Kim, S., Kim, J. W., Roh, K. J., Seong, J. K., Lee, N. T., Choi, K., Kim, K., & Ahn, Y. (2002) · Diabetes · doi:10.2337/diabetes.51.3.676 · Cited by 86
Matsuda, M., DeFronzo, R. A., Glass, L. C., Consoli, A., Giordano, M., Bressler, P., & DelPrato, S. (2002) · Metabolism · doi:10.1053/meta.2002.34700 · Cited by 85
Self-citationImpaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism
Jallut, D., Golay, A., Munger, R., Frascarolo, P., Schutz, Y., Jéquier, E., & Felber, J. P. (1990) · Metabolism · doi:10.1016/0026-0495(90)90168-c · Cited by 83
Rosiglitazone RECORD study: glucose control outcomes at 18 months
Home, P., Jones, N. P., Pocock, S., Beck‐Nielsen, H., Gomis, R., Hanefeld, M., Michel Komajda, N., Curtis, P. S., & for the RECORD Study Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02160.x · Cited by 82
Masuda, K., Okamoto, Y., Tsuura, Y., Kato, S., Miura, T., Tsuda, K., Horikoshi, H., Ishida, H., & Seino, Y. (1995) · Diabetologia · doi:10.1007/bf02369349 · Cited by 77
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., DeFronzo, R. A., & Ferrannini, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1159 · Cited by 75
Self-citationLiutkus, J., Guzmán, J. R., Norwood, P. C., Pop, L., Northrup, J., Cao, D., & TRAUTMANN, M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74
Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs
Johnsen, S. P., Monster, T. B. M., Olsen, M. L., Horsdal, H. T., McLaughlin, J. K., Sørensen, H. T., Lervang, H.-H., & Rungby, J. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200603000-00009 · Cited by 73
Takahashi, A., Nagashima, K., Hamasaki, A., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.021 · Cited by 71
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 68
Lupi, R., Guerra, S. D., Tellini, C., GIANNARELLI, R., Coppelli, A., Lorenzetti, M. H., Carmellini, M., Mosca, F., Navalesi, R., & Marchetti, P. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00807-3 · Cited by 67
Vildagliptin: a new oral treatment for type 2 diabetes mellitus
Mathieu, C., & DEGRANDE, E. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3005 · Cited by 65
Genes and type 2 diabetes mellitus
Groop, L., & Lyssenko, V. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0033-y · Cited by 63
Oxysterols induce interleukin‐1β production in human macrophages
Rosklint, T., Ohlsson, B. G., Wiklund, O., Norén, K., & Hultén, L. M. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00931.x · Cited by 63
Rosenstock, J., Goldstein, B. J., Vinik, A., O’Neill, M., Porter, L. E., Heise, M. A., Kravitz, B. G., Dirani, R. G., Freed, M. I., & and the RESULT Study Group (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00541.x · Cited by 62
Risk of Fractures with Glitazones: A Critical Review of the Evidence to Date
Bodmer, M., Meier, C., KRAENZLIN, M. E., & Meier, C. R. (2009) · Drug Safety · doi:10.2165/00002018-200932070-00001 · Cited by 61
Alvarsson, M., Sundkvist, G., Lager, I., Berntorp, K. E., Fernqvist‐Forbes, E., Steen, L., Örn, T., Holberg, M. A., Kirksæther, N., & Grill, V. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00719.x · Cited by 60
The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance
Zimmet, P., Whitehouse, S., ALFORD, F. P., & Chisholm, D. J. (1978) · Diabetologia · doi:10.1007/bf01219323 · Cited by 57
Khalangot, M. D., Tronko, M. D., Kravchenko, V. I., & Kovtun, V. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.008 · Cited by 56
The metabolic consequences of long-term human obesity.
Felber, J.-P., Golay, A., Jéquier, E., Curchod, B., Temler, E., DeFronzo, R., & Ferrannini, E. (1988) · PubMed · Cited by 55
Self-citationDiamond, M. P., Thornton, K. L., Connolly-Diamond, M., Sherwin, R. S., & DeFronzo, R. A. (1995) · Journal of the Society for Gynecologic Investigation · doi:10.1016/1071-5576(95)00023-8 · Cited by 54
Self-citationPROactive: time for a critical appraisal
Betteridge, D. J., DeFronzo, R. A., & CHILTON, R. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn114 · Cited by 53
Self-citationLincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Pérez, A., Zhao, Z., Jacks, R., & Spanheimer, R. G. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903350011 · Cited by 52
Hanefeld, M., Pfützner, A., Forst, T. M., & Lübben, G. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112598 · Cited by 51
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50
Self-citationNieszner, É., Pósa, I., Kocsis, E., et al. (2002) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2002-33069 · Cited by 42
Hambrock, A., Franz, C. B. D. O., Hiller, S., & Oßwald, H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097501 · Cited by 41
Sillars, B. A., Davis, W. A., Hirsch, I. B., & Davis, T. M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01230.x · Cited by 39
Effect of PPAR-γ Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells
Santini, E., Fallahi, P., Ferrari, S. M., Masoni, A., Antonelli, A., & Ferrannini, E. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s79 · Cited by 39
Abdul‐Ghani, M. A., Matsuda, M., Sabbah, M., Jenkinson, C. P., Richardson, D. K., Kaku, K., & DeFronzo, R. A. (2007) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.02.004 · Cited by 35
Self-citationPanicker, G. K., Karnad, D. R., Salvi, V., & Kothari, S. (2012) · PubMed · Cited by 35
Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis
Kim, J., Lim, D.-M., Park, H.-S., Moon, C., Choi, K.-J., Lee, S., Baik, H., Park, K., & Kim, B.-J. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11072fp · Cited by 30
Jenkins, A. J., Krishnamurthy, B., Best, J. D., Cameron, F. J., Colman, P. G., Farish, S., Hamblin, P. S., O’Connell, M. A., Rodda, C. P., Rowley, K., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1481 · Cited by 29
Aso, Y., Hara, K., Ozeki, N., Yatsuka, C., Nakano, T., Matsumoto, S., Suetsugu, M., Nakamachi, T., Takebayashi, K., Haruki, K., et al. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.05.015 · Cited by 28
Alvarsson, M., Berntorp, K. E., Fernqvist‐Forbes, E., Lager, I., Steen, L., Örn, T., & Grill, V. (2010) · PubMed Central · doi:10.1900/rds.2010.7.225 · Cited by 27
Yokoyama, J., Sutoh, N., Higuma, T., Horiuchi, D., Katoh, C., Yokota, T., Echizen, T., Sasaki, S., Hanada, H., Osanai, T., et al. (2007) · Heart and Vessels · doi:10.1007/s00380-006-0951-z · Cited by 20
Miyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J., & Defronzo, R. A. (2005) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514050050010601 · Cited by 18
Self-citationEfficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
Karyekar, C. S., Donovan, M., Allen, E., Fleming, D., Ravichandran, S., & Chen, R. K. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2305 · Cited by 17
Combination Therapy in Type 2 Diabetes
Bajaj, M., & DeFronzo, R. A. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0613 · Cited by 11
Self-citationUKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationMechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation
Mohamed, J., H., N. N. A., H., Z. A., & B., B. S. (2016) · Sultan Qaboos University Medical Journal · doi:10.18295/squmj.2016.16.02.002 · Cited by 473
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Matthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32131-2 · Cited by 364
Haw, J. S., Galaviz, K. I., Straus, A. N., Kowalski, A. J., Magee, M. J., Weber, M. B., Wei, J., Narayan, K. M. V., & Ali, M. K. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6040 · Cited by 354
Metadata
- Authors
- DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S127-S138
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2029145065
- Cited by
- 314
- References
- 197
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.